Canada markets closed

Telix Pharmaceuticals Limited (TLPPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.2400+0.2400 (+6.00%)
At close: 11:24AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.0000
Open4.2400
BidN/A x N/A
AskN/A x N/A
Day's Range4.2400 - 4.2400
52 Week Range0.9500 - 5.0000
Volume6,825
Avg. Volume2,443
Market Cap1.194B
Beta (5Y Monthly)2.38
PE Ratio (TTM)N/A
EPS (TTM)-0.1290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations
    GlobeNewswire

    Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations

    MELBOURNE, Australia, July 11, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that Ms. Kyahn Williamson has joined the Telix executive leadership team in the role of Senior Vice President of Corporate Communications and Investor Relations. Kyahn joins Telix from WE Communications, where she was Group Head of Investor and Corporate Communication. Over the past 15 years, Kyahn has worked with a wide range of ASX-listed companies spa

  • First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
    GlobeNewswire

    First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

    MELBOURNE, Australia, June 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase I study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with urothelial carcinoma or bladder cancer at Fiona Stanley Hospital in Perth, Western Australia. The objective of the ZiP-UP (Zirconium-girentuximab PET in Urothelial Cancer Patients) study is to evaluate the feasibility of using TLX250-CDx PET/CT1 in the

  • Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
    Business Wire

    Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

    MELBOURNE, Australia & INDIANAPOLIS, Jun 14, 2021--Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research